---
authors:
- Rockafellow, Jessica
- Rattenni, Joseph
category: Clinical Review
clinical_significance: High
external_resources:
- title: PubMed Entry
  type: reference
  url: https://pubmed.ncbi.nlm.nih.gov/37843937/
file_path: 2023/10/thiazide-diuretics-vs-other-antihypertensive-drug-classes-fo.md
issue: '4'
keywords:
- Humans
- Hypertension
- Antihypertensive Agents
- Sodium Chloride Symporter Inhibitors
- Diuretics
last_updated: '2025-07-30'
mesh_terms:
- Humans
- Antihypertensive Agents
- Sodium Chloride Symporter Inhibitors
- Hypertension
- Diuretics
original_format: PubMed
pages: Online
patient_population: Adults
peer_reviewed: true
pmid: '37843937'
processed_date: '2025-07-30'
publication_date: '2023-10-01'
pubmed_enriched: true
pubmed_enriched_date: '2025-07-30'
reading_time_minutes: 5
source: American family physician
specialty:
- Family Medicine
status: processed
tags:
- clinical-review
- family-practice
- clinical-medicine
- pubmed-enhanced
title: Thiazide Diuretics vs. Other Antihypertensive Drug Classes for First-Line Treatment of Hypertension.
topics:
- Hypertension
- Family Medicine
- Cardiovascular Disease
- Blood Pressure
volume: '108'
---

# Thiazide Diuretics vs. Other Antihypertensive Drug Classes for First-Line Treatment of Hypertension.

**Authors:** Rockafellow, Jessica, Rattenni, Joseph

**Published in:** American family physician | Vol. 108, No. 4 | 2023-10-01

**Links:** [PubMed](https://pubmed.ncbi.nlm.nih.gov/37843937/)

## Clinical Information

**Population:** Adults | **Clinical Significance:** High

## Topics & Specialties

**Specialties:** Family Medicine

**Topics:** Hypertension, Family Medicine, Cardiovascular Disease, Blood Pressure

## MeSH Terms

Humans, Antihypertensive Agents, Sodium Chloride Symporter Inhibitors, Hypertension, Diuretics

## Article Content

*Full article content to be extracted and formatted from source material.*

## Additional Resources

- [PubMed Entry](https://pubmed.ncbi.nlm.nih.gov/37843937/) (reference)

---

*Processed: 2025-07-30* | *PubMed Enhanced: 2025-07-30*
